Taseko Mines Provides Construction Update for Florence Copper

VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) — Taseko Mines Limited (TSX: TKO; NYSE MKT: TGB; LSE: TKO) (“Taseko” or the “Company”) is pleased to provide a progress update for construction activities at its Florence Copper project. To date, approximately 300,000 project hours have been worked and there have been no reportable injuries or […]

Lancaster Resources Provides Corporate Update

VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR | OTC:LANRF | FRA:6UF0) (the “Company” or “Lancaster”) is pleased to provide a corporate update. The Company’s portfolio of projects includes the Piney Lake Gold Project, Catley Lake and Centennial East Uranium Projects in Saskatchewan, the Alkali Flat Lithium Brine Project In

Life Biosciences Presents at AAO Highlighting Progress of Nonhuman Primate Studies Evaluating Partial Epigenetic Reprogramming to Restore Visual Function

BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) — Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, today announced new data presented at the 2024 American Association of Ophthalmology (AAO) Annual Meeting that took place in Chicago, Illinois from October

5E Advanced Materials Reports Steady State Operations and Obtains Tax Exclusion For Lithium Capex

HESPERIA, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) — 5E Advanced Materials, Inc. (Nasdaq: FEAM) (ASX: 5EA) (“5E” or the “Company”), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas Complex, is pleased to report positive progress at the Company’s Small-Scale Facility (“SSF”). Highlights: Operational focus and rigor at

Windtree To Present at the ThinkEquity Conference on October 30th

WARRINGTON, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Craig Fraser, Chairman and Chief Executive Officer, will be presenting a corporate update at the ThinkEquity Conference on Oct

Cyabra to Present at the ThinkEquity Conference in New York City on October 30

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) — Cyabra Strategy Ltd. (“Cyabra”), a leading provider of an AI-powered solution for combating worldwide disinformation, today announced that Dan Brahmy, Chief Executive Officer and Co-Founder, will present in person at the ThinkEquity Conference in New York, NY, on Wednesday, October 30, 2024, at 12:00pm ET. Management will

Music Licensing, Inc. (OTC: SONG) Retains SmallCapVoice.com Inc. (“SCV”) to Provide Investor Relations Services

Naples, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading diversified music rights management company, announces today it has retained Austin, Texas-based SmallCapVoice.com Inc. (“SCV”). SmallCapVoice.com, Inc. is an investor relations and communications firm focused on emerging growth companies. Music Licensing, Inc. and SCV will be creating several different initiatives

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma

FDA sets a PDUFA target action date of March 20, 2025 Resubmission is supported by the final survival analysis of CARES-310 study, presented at ASCO 2024 FORT LEE, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the U.S. Food and Drug Administration (FDA) accepted

COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting(R) 2024

Detailed safety and efficacy results to be presented Data show potential of CNP-104 to slow disease progression as demonstrated by statistically significant decrease in liver stiffness compared with placebo CHICAGO, Oct. 21, 2024 (GLOBE NEWSWIRE) — COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed to induce antigen-specific tolerance for autoimmune diseases, today

Taboola Signs Exclusive Deal with National World and Axiom Media Alliance (AMA) to Power Content Recommendations Across the National World Network of Regional Sites Including Yorkshire Evening Post and The Scotsman

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open web, has signed an exclusive multi-year partnership with National World, one of the UK’s largest regional publishers reaching more than 15 million monthly visitors. The London Stock Exchange-listed National World is now implementing Taboola’s suite

Scroll to Top